Statistical considerations for immunohistochemistry panel development after expression profiling of human cancers

Rebecca Betensky, Catherine L. Nutt, Tracy T. Batchelor, David N. Louis

Research output: Contribution to journalArticle

Abstract

In recent years there have been a number of microarray expression studies in which different types of tumors were classified by identifying a panel of differentially expressed genes. Immunohistochemistry is a practical and robust method for extending gene expression data to common pathological specimens with the advantage of being applicable to paraffin-embedded tissues. However, the number of assays required for successful immunohistochemical classification remains unclear. We propose a simulation-based method for assessing sample size for an immunohistochemistry investigation after a promising gene expression study of human tumors. The goals of such an immunohistochemistry study would be to develop and validate a marker panel that yields improved prognostic classification of cancer patients. We demonstrate how the preliminary gene expression data, coupled with certain realistic assumptions, can be used to estimate the number of immunohistochemical assays required for development These assumptions are more tenable than alternative assumptions that would be required for crude analytic sample size calculations and that may yield underpowered and inefficient studies. We applied our methods to the design of an immunohistochemistry study for glioma classification and estimated the number of assays required to ensure satisfactory technical and prognostic validation. Simulation approaches for computing power and sample size that are based on existing gene expression data provide a powerful tool for efficient design of follow-up genomic studies.

Original languageEnglish (US)
Pages (from-to)276-282
Number of pages7
JournalJournal of Molecular Diagnostics
Volume7
Issue number2
DOIs
StatePublished - Jan 1 2005

Fingerprint

Immunohistochemistry
Sample Size
Gene Expression
Neoplasms
Glioma
Paraffin
Genes

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Medicine

Cite this

Statistical considerations for immunohistochemistry panel development after expression profiling of human cancers. / Betensky, Rebecca; Nutt, Catherine L.; Batchelor, Tracy T.; Louis, David N.

In: Journal of Molecular Diagnostics, Vol. 7, No. 2, 01.01.2005, p. 276-282.

Research output: Contribution to journalArticle

@article{391524a1527144b5ade6b427d29474eb,
title = "Statistical considerations for immunohistochemistry panel development after expression profiling of human cancers",
abstract = "In recent years there have been a number of microarray expression studies in which different types of tumors were classified by identifying a panel of differentially expressed genes. Immunohistochemistry is a practical and robust method for extending gene expression data to common pathological specimens with the advantage of being applicable to paraffin-embedded tissues. However, the number of assays required for successful immunohistochemical classification remains unclear. We propose a simulation-based method for assessing sample size for an immunohistochemistry investigation after a promising gene expression study of human tumors. The goals of such an immunohistochemistry study would be to develop and validate a marker panel that yields improved prognostic classification of cancer patients. We demonstrate how the preliminary gene expression data, coupled with certain realistic assumptions, can be used to estimate the number of immunohistochemical assays required for development These assumptions are more tenable than alternative assumptions that would be required for crude analytic sample size calculations and that may yield underpowered and inefficient studies. We applied our methods to the design of an immunohistochemistry study for glioma classification and estimated the number of assays required to ensure satisfactory technical and prognostic validation. Simulation approaches for computing power and sample size that are based on existing gene expression data provide a powerful tool for efficient design of follow-up genomic studies.",
author = "Rebecca Betensky and Nutt, {Catherine L.} and Batchelor, {Tracy T.} and Louis, {David N.}",
year = "2005",
month = "1",
day = "1",
doi = "10.1016/S1525-1578(10)60555-7",
language = "English (US)",
volume = "7",
pages = "276--282",
journal = "Journal of Molecular Diagnostics",
issn = "1525-1578",
publisher = "Association of Molecular Pathology",
number = "2",

}

TY - JOUR

T1 - Statistical considerations for immunohistochemistry panel development after expression profiling of human cancers

AU - Betensky, Rebecca

AU - Nutt, Catherine L.

AU - Batchelor, Tracy T.

AU - Louis, David N.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - In recent years there have been a number of microarray expression studies in which different types of tumors were classified by identifying a panel of differentially expressed genes. Immunohistochemistry is a practical and robust method for extending gene expression data to common pathological specimens with the advantage of being applicable to paraffin-embedded tissues. However, the number of assays required for successful immunohistochemical classification remains unclear. We propose a simulation-based method for assessing sample size for an immunohistochemistry investigation after a promising gene expression study of human tumors. The goals of such an immunohistochemistry study would be to develop and validate a marker panel that yields improved prognostic classification of cancer patients. We demonstrate how the preliminary gene expression data, coupled with certain realistic assumptions, can be used to estimate the number of immunohistochemical assays required for development These assumptions are more tenable than alternative assumptions that would be required for crude analytic sample size calculations and that may yield underpowered and inefficient studies. We applied our methods to the design of an immunohistochemistry study for glioma classification and estimated the number of assays required to ensure satisfactory technical and prognostic validation. Simulation approaches for computing power and sample size that are based on existing gene expression data provide a powerful tool for efficient design of follow-up genomic studies.

AB - In recent years there have been a number of microarray expression studies in which different types of tumors were classified by identifying a panel of differentially expressed genes. Immunohistochemistry is a practical and robust method for extending gene expression data to common pathological specimens with the advantage of being applicable to paraffin-embedded tissues. However, the number of assays required for successful immunohistochemical classification remains unclear. We propose a simulation-based method for assessing sample size for an immunohistochemistry investigation after a promising gene expression study of human tumors. The goals of such an immunohistochemistry study would be to develop and validate a marker panel that yields improved prognostic classification of cancer patients. We demonstrate how the preliminary gene expression data, coupled with certain realistic assumptions, can be used to estimate the number of immunohistochemical assays required for development These assumptions are more tenable than alternative assumptions that would be required for crude analytic sample size calculations and that may yield underpowered and inefficient studies. We applied our methods to the design of an immunohistochemistry study for glioma classification and estimated the number of assays required to ensure satisfactory technical and prognostic validation. Simulation approaches for computing power and sample size that are based on existing gene expression data provide a powerful tool for efficient design of follow-up genomic studies.

UR - http://www.scopus.com/inward/record.url?scp=18744365499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18744365499&partnerID=8YFLogxK

U2 - 10.1016/S1525-1578(10)60555-7

DO - 10.1016/S1525-1578(10)60555-7

M3 - Article

C2 - 15858152

AN - SCOPUS:18744365499

VL - 7

SP - 276

EP - 282

JO - Journal of Molecular Diagnostics

JF - Journal of Molecular Diagnostics

SN - 1525-1578

IS - 2

ER -